NANJING VISHEE MEDICAL TECHNOLOGY CO., LTD Nanjing Vishee Medical Technology Co., Ltd Share Price
Equities
688580
CNE1000041Q0
Advanced Medical Equipment & Technology
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.19 CNY | -1.53% |
|
+4.27% | -29.31% |
| Sales 2024 * | 572M 78.98M 6.59B | Sales 2025 * | 696M 96.1M 8.02B | Capitalization | 3.07B 424M 35.39B |
|---|---|---|---|---|---|
| Net income 2024 * | 170M 23.48M 1.96B | Net income 2025 * | 209M 28.86M 2.41B | EV / Sales 2024 * | 5.37 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.42 x |
| P/E ratio 2024 * |
18.3
x | P/E ratio 2025 * |
14.9
x | Employees | 700 |
| Yield 2024 * |
3.97% | Yield 2025 * |
4.79% | Free-Float | 31.46% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.53% | ||
| 1 week | +4.27% | ||
| 1 month | -1.53% | ||
| 3 months | -15.06% | ||
| 6 months | -33.96% | ||
| Current year | -29.31% |
1 week
43.22
46.25
1 month
43.0049.00
Current year
36.6663.96
1 year
36.6675.46
3 years
36.66180.99
5 years
36.66237.00
10 years
36.66237.00
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Yu Wang
CEO | Chief Executive Officer | 57 | 10/01/10 |
Li Li Chen
DFI | Director of Finance/CFO | 44 | 01/09/01 |
Hui Zhang
COO | Chief Operating Officer | 43 | 12/21/12 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wen Hua Cai
BRD | Director/Board Member | 44 | 01/19/01 |
Zhi Yu Wang
CEO | Chief Executive Officer | 57 | 10/01/10 |
| - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 45.19 | -1.53% | 320,798 |
| 30/24/30 | 45.89 | +4.18% | 795,080 |
| 29/24/29 | 44.05 | +1.54% | 327,373 |
| 28/24/28 | 43.38 | -1.81% | 239,568 |
| 27/24/27 | 44.18 | +1.94% | 309,680 |
End-of-day quote Shanghai S.E., May 31, 2024
More quotes
Nanjing Vishee Medical Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of rehabilitation medical equipment and products. The Companyâs products are mainly electrical stimulation, magnetic stimulation, electrophysiological equipment, consumables and accessories and other rehabilitation medical equipment and products, such as pelvic floor muscle recovery equipment, transcranial magnetic stimulator, neonatal electroencephalography measuring instrument, rectal electrode, micro current stimulator and others. The Company mainly conducts its businesses within the domestic market.
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
45.19
CNY
Average target price
59.66
CNY
Spread / Average Target
+32.02%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -29.31% | 424M | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| +13.95% | 52.36B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.6B |
- Stock Market
- Equities
- 688580 Stock
